{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:47:56Z","timestamp":1786996076567,"version":"build-2736575974"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.psc.2016.07.012","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T13:15:36Z","timestamp":1478610936000},"page":"541-556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Psychopharmacology of Persistent Violence and Aggression"],"prefix":"10.1016","volume":"39","author":[{"given":"Jonathan M.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psc.2016.07.012_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1017\/S1092852914000054","article-title":"The psychopharmacology of violence: making sensible decisions","volume":"19","author":"Citrome","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2016.07.012_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.psc.2012.08.009","article-title":"Psychopharmacologic management of aggression","volume":"35","author":"Newman","year":"2012","journal-title":"Psychiatr Clin North Am"},{"issue":"4","key":"10.1016\/j.psc.2016.07.012_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003299.pub2","article-title":"Pharmacological management for agitation and aggression in people with acquired brain injury","author":"Fleminger","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2016.07.012_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/YCO.0b013e32835f414b","article-title":"Agitation and aggression in people with Alzheimer's disease","volume":"26","author":"Ballard","year":"2013","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2016.07.012_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003079.pub3","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","author":"Gillies","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2016.07.012_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S1092852914000376","article-title":"California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines","volume":"19","author":"Stahl","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2016.07.012_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1017\/S1092852914000820","article-title":"Inpatient aggression in community hospitals","volume":"20","author":"Szabo","year":"2015","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2016.07.012_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ridd.2005.05.002","article-title":"Guidelines for the use of clozapine in individuals with developmental disabilities","volume":"27","author":"Sabaawi","year":"2006","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.psc.2016.07.012_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ridd.2008.10.010","article-title":"Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities","volume":"30","author":"de Leon","year":"2009","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.psc.2016.07.012_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2788.2009.01232.x","article-title":"Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment?","volume":"54","author":"Tsiouris","year":"2010","journal-title":"J\u00a0Intellect Disabil Res"},{"key":"10.1016\/j.psc.2016.07.012_bib11","series-title":"A\u00a0Practitioner's guide to prescribing antiepileptics and mood stabilizers for adults with intellectual disabilities","year":"2012"},{"key":"10.1016\/j.psc.2016.07.012_bib12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1176\/appi.ps.54.7.1012","article-title":"Characteristics of assaultive behavior among psychiatric inpatients","volume":"54","author":"Nolan","year":"2003","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.psc.2016.07.012_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1176\/ps.2007.58.4.521","article-title":"Categorization of aggressive acts committed by chronically assaultive state hospital patients","volume":"58","author":"Quanbeck","year":"2007","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.psc.2016.07.012_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1017\/S1092852914000224","article-title":"Assessment of aggression in inpatient settings","volume":"19","author":"McDermott","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2016.07.012_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1176\/appi.ajp.2008.07111774","article-title":"Neurobiology of aggression and violence","volume":"165","author":"Siever","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1017\/S1092852914000522","article-title":"Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits","volume":"19","author":"Stahl","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2016.07.012_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1017\/S109285291500019X","article-title":"The neurobiology of aggression and violence","volume":"20","author":"Rosell","year":"2015","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2016.07.012_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/cap.2015.0088","article-title":"The neurobiology of impulsive aggression","volume":"26","author":"Blair","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2016.07.012_bib19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/mp.2015.140","article-title":"From impulses to maladaptive actions: the insula is a neurobiological gate for the development of compulsive behavior","volume":"21","author":"Belin-Rauscent","year":"2016","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.avb.2008.06.003","article-title":"Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders","volume":"13","author":"Seo","year":"2008","journal-title":"Aggress Violent Behav"},{"key":"10.1016\/j.psc.2016.07.012_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13353-011-0069-6","article-title":"Genetic determinants of aggression and impulsivity in humans","volume":"53","author":"Pavlov","year":"2012","journal-title":"J\u00a0Appl Genet"},{"key":"10.1016\/j.psc.2016.07.012_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ab.20339","article-title":"Aggressive behavior, related conduct problems, and variation in genes affecting dopamine turnover","volume":"36","author":"Grigorenko","year":"2010","journal-title":"Aggress Behav"},{"key":"10.1016\/j.psc.2016.07.012_bib23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1017\/S1092852915000206","article-title":"Impulsivity and aggression in schizophrenia: a neural circuitry perspective with implications for treatment","volume":"20","author":"Hoptman","year":"2015","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2016.07.012_bib24","series-title":"Polypharmacy in psychiatry practice, Volume I: multiple medication use strategies","first-page":"107","article-title":"Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy?","author":"Stahl","year":"2013"},{"key":"10.1016\/j.psc.2016.07.012_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1017\/S1092852914000388","article-title":"Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy","volume":"19","author":"Morrissette","year":"2014","journal-title":"CNS Spectr"},{"issue":"Suppl 2","key":"10.1016\/j.psc.2016.07.012_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4088\/JCP.9096su1cc.03","article-title":"Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation","volume":"71","author":"Vieta","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4088\/JCP.10m06529","article-title":"Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST)","volume":"72","author":"Volavka","year":"2011","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1017\/S1092852913000849","article-title":"Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study","volume":"19","author":"Volavka","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2016.07.012_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1176\/appi.neuropsych.13110335","article-title":"Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review","volume":"26","author":"Victoroff","year":"2014","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.psc.2016.07.012_bib30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1017\/S1092852914000236","article-title":"A\u00a0rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes","volume":"19","author":"Meyer","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2016.07.012_bib31","first-page":"269","article-title":"Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance","volume":"29","author":"Simpson","year":"1968","journal-title":"Dis Nerv Syst"},{"key":"10.1016\/j.psc.2016.07.012_bib32","series-title":"Handbook of treatment-resistant schizophrenia","author":"Citrome","year":"2013"},{"key":"10.1016\/j.psc.2016.07.012_bib33","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.jcp.0000096246.29231.73","article-title":"The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind, crossover study","volume":"23","author":"Conley","year":"2003","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.07.012_bib34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-012-2922-7","article-title":"Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?","volume":"225","author":"Remington","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psc.2016.07.012_bib35","series-title":"Clozapine handbook","author":"Bleakley","year":"2013"},{"key":"10.1016\/j.psc.2016.07.012_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.2011.01792.x","article-title":"Augmentation of clozapine with a second antipsychotic - a meta-analysis","volume":"125","author":"Taylor","year":"2012","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.psc.2016.07.012_bib37","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/archpsyc.63.6.622","article-title":"Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Krakowski","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4088\/JCP.11m07238","article-title":"Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial","volume":"73","author":"Krakowski","year":"2012","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib39","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1017\/S146114571100201X","article-title":"A\u00a0systematic review of the evidence of clozapine's anti-aggressive effects","volume":"15","author":"Frogley","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.psc.2016.07.012_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S1092852914000157","article-title":"Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital","volume":"19","author":"Brown","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2016.07.012_bib41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4088\/JCP.v67n0702","article-title":"Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: a systematic review","volume":"67","author":"Goedhard","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib42","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2165\/11596930-000000000-00000","article-title":"Pharmacological management of acute and persistent aggression in forensic psychiatry settings","volume":"25","author":"Citrome","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psc.2016.07.012_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000314309","article-title":"Lithium reduces pathological aggression and suicidality: a mini-review","volume":"62","author":"Muller-Oerlinghausen","year":"2010","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.psc.2016.07.012_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1192\/bjp.bp.110.083030","article-title":"Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis","volume":"198","author":"Jones","year":"2011","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib45","doi-asserted-by":"crossref","DOI":"10.1017\/S1092852915000796","article-title":"Stimulant medications for treatment of impulsive violence in schizophrenic female forensic patients: a case series.","author":"Skoretz","year":"2016","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.psc.2016.07.012_bib46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rehab.2015.10.003","article-title":"Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice","volume":"59","author":"Plantier","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"key":"10.1016\/j.psc.2016.07.012_bib47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.HTR.0000314532.07530.e5","article-title":"The use of atypical antipsychotics after traumatic brain injury","volume":"23","author":"Elovic","year":"2008","journal-title":"J\u00a0Head Trauma Rehabil"},{"key":"10.1016\/j.psc.2016.07.012_bib48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.psc.2016.07.012_bib49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/jcpt.12286","article-title":"Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine","volume":"40","author":"Akamine","year":"2015","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.psc.2016.07.012_bib50","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.psc.2016.07.012_bib51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.genhosppsych.2005.02.001","article-title":"Rapid oral loading of extended release divalproex in patients with acute mania","volume":"27","author":"Miller","year":"2005","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/neu.2015.17","article-title":"The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke","volume":"27","author":"Sami","year":"2015","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.psc.2016.07.012_bib53","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/01.HTR.0000438116.56228.de","article-title":"Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression","volume":"29","author":"Hammond","year":"2014","journal-title":"J\u00a0Head Trauma Rehabil"},{"key":"10.1016\/j.psc.2016.07.012_bib54","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1089\/neu.2014.3803","article-title":"Amantadine effect on perceptions of irritability after traumatic brain injury: results of the Amantadine Irritability Multisite Study","volume":"32","author":"Hammond","year":"2015","journal-title":"J\u00a0Neurotrauma"},{"issue":"4","key":"10.1016\/j.psc.2016.07.012_bib55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jagp.2013.06.007","article-title":"Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study","volume":"22","author":"Langballe","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib56","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/HRP.0000000000000097","article-title":"Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease: A Review of the Literature","volume":"23","author":"McClam","year":"2015","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib58","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1176\/appi.ajp.2015.15010130","volume":"173","author":"Ballard","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2016.07.012_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008634.pub2","article-title":"Psychosocial interventions for reducing antipsychotic medication in care home residents","author":"Richter","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2016.07.012_bib60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cns.12484","article-title":"Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer's Disease and Dementia with Lewy Bodies","volume":"22","author":"Cummings","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.psc.2016.07.012_bib61","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JAD-131190","article-title":"Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial","volume":"39","author":"Cumbo","year":"2014","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.psc.2016.07.012_bib62","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3233\/JAD-132735","article-title":"Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study","volume":"41","author":"Gareri","year":"2014","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.psc.2016.07.012_bib63","unstructured":"Eisai Inc. Aricept [Package Insert]. Woodcliff Lake, NJ 07677: Eisai Inc; 2015."},{"key":"10.1016\/j.psc.2016.07.012_bib64","unstructured":"Forest Pharmaceuticals Inc. Namenda XR [Package Insert]. St Louis, MO 63045: Forest Pharmaceuticals LLC; 2014."},{"issue":"2","key":"10.1016\/j.psc.2016.07.012_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008191.pub2","article-title":"Antidepressants for agitation and psychosis in dementia","author":"Seitz","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.psc.2016.07.012_bib66","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.2016.15020248","article-title":"Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study","volume":"173","author":"Leonpacher","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2016.07.012_bib67","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1176\/appi.ajp.2015.15050648","article-title":"Heterogeneity of treatment response to citalopram for patients with Alzheimer's Disease with aggression or agitation: the CitAD randomized clinical trial","volume":"173","author":"Schneider","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib68","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1017\/S1041610215001106","article-title":"Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial","volume":"27","author":"Rosenberg","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.psc.2016.07.012_bib69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.psym.2014.09.002","article-title":"Citalopram, QTc prolongation, and torsades de pointes","volume":"56","author":"Tampi","year":"2015","journal-title":"Psychosomatics"},{"key":"10.1016\/j.psc.2016.07.012_bib70","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1212\/WNL.55.9.1271","article-title":"Treatment of agitation in AD: a randomized, placebo-controlled clinical trial","volume":"55","author":"Teri","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.psc.2016.07.012_bib71","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.psc.2016.07.012_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003476.pub2","article-title":"The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease","author":"Ballard","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2016.07.012_bib73","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease","volume":"355","author":"Schneider","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.psc.2016.07.012_bib74","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2011.11030347","article-title":"Risk of mortality among individual antipsychotics in patients with dementia","volume":"169","author":"Kales","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib75","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/gps.1792","article-title":"The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials","volume":"22","author":"Katz","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"issue":"Suppl 11","key":"10.1016\/j.psc.2016.07.012_bib76","first-page":"11","article-title":"Efficacy of atypical antipsychotics in elderly patients with dementia","volume":"65","author":"Tariot","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2016.07.012_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007726.pub2","article-title":"Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia","author":"Declercq","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2016.07.012_bib78","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s40265-014-0293-6","article-title":"Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy?","volume":"74","author":"Gallagher","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.psc.2016.07.012_bib79","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/alzrt201","article-title":"Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012","volume":"5","author":"Herrmann","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.psc.2016.07.012_bib80","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0897190011424802","article-title":"Valproic acid in dementia: does an optimal dose exist?","volume":"25","author":"Dolder","year":"2012","journal-title":"J\u00a0Pharm Pract"},{"key":"10.1016\/j.psc.2016.07.012_bib81","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/psyg.12085","article-title":"Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer's disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial","volume":"15","author":"Suzuki","year":"2015","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.psc.2016.07.012_bib82","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/gps.2200","article-title":"Expert opinion on the management of behavioural and psychological symptoms of dementia (BPSD) and investigation into prescribing practices in the UK","volume":"24","author":"Bishara","year":"2009","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib83","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1533317514524813","article-title":"Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials","volume":"29","author":"Tampi","year":"2014","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.psc.2016.07.012_bib84","first-page":"254","article-title":"Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia","volume":"19","author":"Midha","year":"1994","journal-title":"J\u00a0Psychiatry Neurosci"},{"key":"10.1016\/j.psc.2016.07.012_bib85","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.152.2.173","article-title":"D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate","volume":"152","author":"Nyberg","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib86","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archpsyc.1997.01830220079011","article-title":"Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate - preliminary findings.","volume":"54","author":"Nyberg","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial","volume":"21","author":"Perry","year":"2001","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.07.012_bib88","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/hup.781","article-title":"Plasma concentrations of high-dose olanzapine in a double-blind crossover study","volume":"21","author":"Kelly","year":"2006","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.psc.2016.07.012_bib89","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e318218d339","article-title":"Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.07.012_bib90","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/appi.ajp.163.3.396","article-title":"A\u00a0PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone","volume":"163","author":"Remington","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib91","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1017\/S1461145704004924","article-title":"Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia","volume":"8","author":"Gefvert","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.psc.2016.07.012_bib92","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.4088\/JCP.09r05060gre","article-title":"A\u00a0systematic review of aripiprazole\u2013dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring","volume":"71","author":"Sparshatt","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib93","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.07.012_bib94","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s002130050277","article-title":"The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study","volume":"131","author":"Kapur","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psc.2016.07.012_bib95","first-page":"298","article-title":"A\u00a0practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy","volume":"57","author":"Wei","year":"1996","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib96","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0006-3223(85)90063-0","article-title":"Effects of smoking on fluphenazine clearance in psychiatric inpatients","volume":"20","author":"Ereshefsky","year":"1985","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.psc.2016.07.012_bib97","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JCP.0b013e31828b28d5","article-title":"Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response","volume":"33","author":"Bishara","year":"2013","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.07.012_bib98","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-006-0209-9","article-title":"The effect of variable cigarette consumption on the interaction with clozapine and olanzapine","volume":"62","author":"Haslemo","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.psc.2016.07.012_bib99","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone","volume":"51","author":"de Leon","year":"2010","journal-title":"Psychosomatics"},{"key":"10.1016\/j.psc.2016.07.012_bib100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1176\/appi.psy.49.4.347","article-title":"A\u00a0preliminary attempt to personalize risperidone dosing using drug\u2013drug interactions and genetics: part II","volume":"49","author":"de Leon","year":"2008","journal-title":"Psychosomatics"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X16300508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X16300508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T08:50:22Z","timestamp":1718873422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X16300508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0193953X16300508"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2016.07.012","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychopharmacology of Persistent Violence and Aggression","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2016.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}